Literature DB >> 20670739

Nanomedicine in ophthalmology: the new frontier.

Marco A Zarbin1, Carlo Montemagno, James F Leary, Robert Ritch.   

Abstract

PURPOSE: To review the fields of nanotechnology and nanomedicine as they relate to the development of treatments for vision-threatening disorders.
DESIGN: Perspective following literature review.
METHODS: Analysis of relevant publications in the peer-reviewed scientific literature.
RESULTS: Nanotechnology involves the creation and use of materials and devices at the size scale of intracellular structures and molecules and involves systems and constructs on the order of <100 nm. The aim of nanomedicine is the comprehensive monitoring, control, construction, repair, defense, and improvement of human biological systems at the molecular level, using engineered nanodevices and nanostructures, operating massively in parallel at the single cell level, ultimately to achieve medical benefit. The earliest impact of nanomedicine is likely to involve the areas of biopharmaceuticals (eg, drug delivery, drug discovery), implantable materials (eg, tissue regeneration scaffolds, bioresorbable materials), implantable devices (eg, intraocular pressure monitors, glaucoma drainage valves), and diagnostic tools (eg, genetic testing, imaging, intraocular pressure monitoring). Nanotechnology will bring about the development of regenerative medicine (ie, replacement and improvement of cells, tissues, and organs), ultrahigh-resolution in vivo imaging, microsensors and feedback devices, and artificial vision. "Regenerative nanomedicine," a new subfield of nanomedicine, uses nanoparticles containing gene transcription factors and other modulating molecules that allow for the reprogramming of cells in vivo.
CONCLUSIONS: Nanotechnology already has been applied to the measurement and treatment of different disease states in ophthalmology (including early- and late-stage disease), and many additional innovations will occur during the next century. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20670739     DOI: 10.1016/j.ajo.2010.03.019

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  11 in total

Review 1.  Gene therapy in the cornea: 2005--present.

Authors:  Rajiv R Mohan; Jonathan C K Tovey; Ajay Sharma; Ashish Tandon
Journal:  Prog Retin Eye Res       Date:  2011-09-28       Impact factor: 21.198

Review 2.  [Use of nanoparticles in ophthalomology].

Authors:  I Hahn; P Heiduschka; E Endl; N Eter
Journal:  Ophthalmologe       Date:  2011-09       Impact factor: 1.059

Review 3.  The oil spill in ageing Bruch membrane.

Authors:  Christine A Curcio; Mark Johnson; Martin Rudolf; Jiahn-Dar Huang
Journal:  Br J Ophthalmol       Date:  2011-09-02       Impact factor: 4.638

4.  Ocular biocompatibility and structural integrity of micro- and nanostructured poly(caprolactone) films.

Authors:  Daniel A Bernards; Robert B Bhisitkul; Paula Wynn; Mark R Steedman; On-Tat Lee; Fergus Wong; Somanus Thoongsuwan; Tejal A Desai
Journal:  J Ocul Pharmacol Ther       Date:  2013-02-07       Impact factor: 2.671

5.  Single-molecule tracking in living cells using single quantum dot applications.

Authors:  Koichi Baba; Kohji Nishida
Journal:  Theranostics       Date:  2012-07-06       Impact factor: 11.556

Review 6.  Nanomedicine approaches for corneal diseases.

Authors:  Shyam S Chaurasia; Rayne R Lim; Rajamani Lakshminarayanan; Rajiv R Mohan
Journal:  J Funct Biomater       Date:  2015-04-30

Review 7.  Nanomaterials-Tools, Technology and Methodology of Nanotechnology Based Biomedical Systems for Diagnostics and Therapy.

Authors:  Christian Schmidt; Joachim Storsberg
Journal:  Biomedicines       Date:  2015-07-20

8.  Effect of Methylcellulose Molecular Weight on the Properties of Self-Assembling MC-g-PNtBAm Nanogels.

Authors:  Marion Jamard; Heather Sheardown
Journal:  Bioengineering (Basel)       Date:  2018-05-23

9.  Attenuation of corneal myofibroblast development through nanoparticle-mediated soluble transforming growth factor-β type II receptor (sTGFβRII) gene transfer.

Authors:  Ajay Sharma; Jason T Rodier; Ashish Tandon; Alexander M Klibanov; Rajiv R Mohan
Journal:  Mol Vis       Date:  2012-10-20       Impact factor: 2.367

10.  Nanotechnology in ophthalmology.

Authors:  Hira Lal Gupta; Pulkit Gupta; Rekha Gupta
Journal:  Indian J Ophthalmol       Date:  2013-05       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.